Table 2. Correlation between A20 mRNA expression and clinicopathological parameters in HCC patients.
| Parameters | Total number | Relative expression of A20 mRNA | P-value |
|---|---|---|---|
| Gender | 0.352 | ||
| Male | 47 | 9.84 (5.35-14.87) | |
| Female | 16 | 7.42 (3.57-12.70) | |
| Age (years) | 0.133 | ||
| ≤60 | 34 | 11.86 (3.62-16.80) | |
| >60 | 29 | 7.01 (4.59-10.74) | |
| HBeAg | 0.261 | ||
| Negative | 41 | 6.11 (3.01-16.84) | |
| Positive | 22 | 10.08 (7.11-12.99) | |
| HBV DNA | 0.123 | ||
| Negative | 36 | 10.39 (5.23-17.99) | |
| Positive | 27 | 7.14 (3.71-12.40) | |
| Smoking | 0.361 | ||
| No | 25 | 7.04 (3.27-15.88) | |
| Yes | 38 | 10.20 (5.51-13.95) | |
| Alcohol | 0.890 | ||
| No | 28 | 8.34 (4.28-16.32) | |
| Yes | 35 | 9.37 (3.71-13.58) | |
| LC | 0.010 | ||
| Negative | 14 | 5.27 (2.01-6.29) | |
| Positive | 49 | 10.35 (6.45-14.93) | |
| Ascites | 0.021 | ||
| Negative | 42 | 7.09 (3.91-11.78) | |
| Positive | 21 | 14.87 (5.81-18.27) | |
| HE | 0.292 | ||
| Negative | 50 | 8.61 (3.84-13.64) | |
| Positive | 13 | 12.40 (5.36-16.84) | |
| Variceal bleeding | 0.688 | ||
| Negative | 35 | 8.85 (3.33-16.90) | |
| Positive | 28 | 9.98 (5.92-12.83) | |
| AFP | 0.379 | ||
| ≤20 | 22 | 7.03 (2.60-16.80) | |
| >20 | 41 | 9.84 (5.72-13.37) | |
| Primary tumor number | 0.076 | ||
| Single | 32 | 7.38 (3.43-11.70) | |
| Multiple | 31 | 11.70 (5.56-16.90) | |
| Tumor size | 0.783 | ||
| ≤3cm | 29 | 10.05 (4.46-14.62) | |
| >3cm | 34 | 8.10 (3.84-14.58) | |
| Venous invasion | 0.040 | ||
| Negative | 43 | 7.14 (3.33-12.40) | |
| Positive | 20 | 13.26 (6.89-17.53) | |
| TNM staging | 0.188 | ||
| I/II | 39 | 7.83 (3.71-12.53) | |
| III/IV | 24 | 10.54 (5.74-17.53) |
HCC, hepatocellular carcinoma; HBeAg, hepatitis B e antigen; LC, liver cirrhosis; HE = hepatic encephalopathy; AFP, alpha-fetoprotein; TNM, tumor node metastasis.